Tracking the path to myeloma: can we predict cancer before it strikes?

NCT ID NCT02726750

Summary

This study aims to understand why some people with early, symptom-free blood cell conditions (MGUS or smoldering myeloma) develop full multiple myeloma while others don't. Researchers will follow 200 patients for 3 years, collecting blood samples and tracking their health to identify markers that predict cancer progression. The goal is to find better ways to identify which patients need closer monitoring or earlier treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.